214 related articles for article (PubMed ID: 11121907)
21. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Bautista J; Fullerton H; Briseno M; Cui H; Fass R
Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
[TBL] [Abstract][Full Text] [Related]
22. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
[TBL] [Abstract][Full Text] [Related]
24. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Richter JE; Kovacs TO; Greski-Rose PA; Huang section sign B; Fisher R
Aliment Pharmacol Ther; 1999 Jun; 13(6):795-804. PubMed ID: 10383510
[TBL] [Abstract][Full Text] [Related]
25. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Castro Fernández M; García Díaz E; Larraona JL; Rodríguez Hornillo MC; Lamas Rojas E; Núñez Hospital D; Pallarés Querol M
Rev Esp Enferm Dig; 2006 Mar; 98(3):170-9. PubMed ID: 16737416
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
30. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Sontag SJ; Schnell TG; Chejfec G; Kurucar C; Karpf J; Levine G
Aliment Pharmacol Ther; 1997 Feb; 11(1):147-56. PubMed ID: 9042987
[TBL] [Abstract][Full Text] [Related]
31. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
Nelson WW; Vermeulen LC; Geurkink EA; Ehlert DA; Reichelderfer M
Arch Intern Med; 2000 Sep; 160(16):2491-6. PubMed ID: 10979061
[TBL] [Abstract][Full Text] [Related]
32. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
33. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects.
Harder H; Teyssen S; Stephan F; Pfützer R; Kiel G; Fuchs W; Singer MV
Scand J Gastroenterol; 1999 Jun; 34(6):551-61. PubMed ID: 10440603
[TBL] [Abstract][Full Text] [Related]
34. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Farup PG; Juul-Hansen PH; Rydning A
J Clin Gastroenterol; 2001 Sep; 33(3):206-9. PubMed ID: 11500608
[TBL] [Abstract][Full Text] [Related]
35. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
36. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
Bardhan KD; Hawkey CJ; Long RG; Morgan AG; Wormsley KG; Moules IK; Brocklebank D
Aliment Pharmacol Ther; 1995 Apr; 9(2):145-51. PubMed ID: 7605854
[TBL] [Abstract][Full Text] [Related]
37. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
Hatlebakk JG; Berstad A
Aliment Pharmacol Ther; 1997 Apr; 11(2):365-72. PubMed ID: 9146777
[TBL] [Abstract][Full Text] [Related]
38. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
39. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
[TBL] [Abstract][Full Text] [Related]
40. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Frazzoni M; Grisendi A; Lanzani A; Melotti G; De Micheli E
Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]